Thrombotic microangiopathies: multimers, metalloprotease, and beyond

Clin Transl Sci. 2009 Oct;2(5):366-73. doi: 10.1111/j.1752-8062.2009.00142.x.

Abstract

The pathophysiology of various types of thrombotic microangiopathies is coming progressively into focus. Therapeutic advances are likely to follow at a quickening pace. This discussion focuses on thrombotic thrombocytopenic purpura (TTP), the hemolytic-uremic syndrome (HUS), thrombotic microangiopathies associated with transplantation-immunosuppression or anti-angiogenesis therapy, and the preeclampsia/hemolysis-elevated liver enzymes and low platelets syndrome (HELLP).

Publication types

  • Review

MeSH terms

  • ADAM Proteins / metabolism
  • ADAMTS13 Protein
  • Angiogenesis Inhibitors / pharmacology
  • Antineoplastic Agents / pharmacology
  • Hemolytic-Uremic Syndrome / diagnosis
  • Hemolytic-Uremic Syndrome / genetics
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Metalloproteases / metabolism*
  • Models, Biological
  • Platelet Adhesiveness
  • Protein Structure, Tertiary
  • Purpura, Thrombotic Thrombocytopenic / diagnosis
  • Purpura, Thrombotic Thrombocytopenic / genetics
  • Thrombotic Microangiopathies / diagnosis*
  • Thrombotic Microangiopathies / enzymology*
  • Thrombotic Microangiopathies / physiopathology
  • von Willebrand Factor / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • von Willebrand Factor
  • Metalloproteases
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human